The global recombinant human growth hormone (RHGH) market was valued at approximately USD 1.77 billion in 2024 and is projected to reach around USD 3.89 billion by 2032, representing a strong CAGR of about 10.30% over the forecast period.
As treatments for growth hormone deficiency, Turner syndrome, idiopathic short stature, and other related conditions...